Nucleus Network is a not-for-profit clinical research and education company wholly owned by the Baker IDI Heart and Diabetes Institute and comprises the AMREP Centre for Clinical Studies (a 30-bed early phase clinical trial unit located on the Alfred Medical Research Education Precinct site), the Austin Centre for Clinical Studies (a 16 bed early phase clinical trial unit located at the Austin Hospital), Clinical Trials Consulting and Nucleus Network Education. The organisation is structured as an independent company limited by guarantee with an independent board. The not-for-profit status provides unique collaborations with hospital based principal investigators, individual researchers, medical schools and access to dedicated research precinct facilities and capabilities.
Nucleus Network is Australia’s leading clinical research organisation specialising in the conduct of Early Phase Clinical Trials. As an industry leader, Nucleus Network follows strict adherence to the highest standards of clinical research, conducted in accordance with international regulatory requirements and expectations. The company is committed to best practice industry-wide.
Early phase clinical trials, conducted at the Centres for Clinical Studies, are a vital step in the process of bringing new and safe medicines to the global community. Every medicine that is sold over the counter or by prescription has undergone stringent clinical testing to ensure it is safe and effective, and it is this process that is undertaken at Nucleus Network. Nucleus Network has conducted numerous studies in various therapeutic areas for multinational pharmaceutical companies and biotechnology companies in therapeutic areas such as heart disease, diabetes, dermatology, hepatitis, metabolic disease and neurosciences. Nucleus Network has expertise to take compounds from pre-clinical all the way to Proof-of-Concept.
Clinical Trials Consulting, is a consultancy group geared toward the local Australian biotech market, to help companies go from pre-clinical studies into the clinic for the first time. Nucleus Network may start working with companies a year before they are ready to move to the clinic – eg providing preclinical gap analysis and assistance with writing drug brochures, generating clinical development plans and assistance to seek out grant funding. Through its involvement in world-class clinical trials for international sponsors, Nucleus Network is able to bring skills and experience to support local Australian biotech companies who are developing new medicines.
Nucleus Network Education collaborates with Australian and international education groups to provide globally recognised career development options for clinical research personnel. Clinical Researchers can access in-class room training and on-line training for Good Clinical Practice and recognition for continuing education.
The organisation has contributed to the study of numerous chemical entities, biologics or peptide compounds in clinical trials forging the discovery of new medicines to improve lives and healthcare around the world. It also provides opportunities for Clinical Research Professional researchers to be involved in innovative technologies and newest innovations. Nucleus Network is also a founding member organisation of Early Phase Clinical Research Australia (EPCRA).
